Platelet inhibition to reduce formation of non-alcohol steatohepatitis in cardiovascular patients
Recruiting
- Conditions
- non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH)
- Registration Number
- DRKS00013025
- Lead Sponsor
- niversitätsklinikum Tübingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Patients with an age from 18-80 years with symptomatic cardiovascular disease and a high-risk profile including diabetes mellitus type II and/or obesity with BMI =30
Exclusion Criteria
History of viral hepatitis
Patients with alcoholic steatohepatitis (ASH)
Pregnancy
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of level of steatosis and fibrosis in patients with NAFLD (non-alcoholic fatty liver disease)/NASH (non-alcoholic steatohepatitis) by administration of antiplatelet therapy<br><br>Diagnosis and evaluation of course of NAFLD/NASH are obtained by liver MRI, Fibroscan, hematologic and clinical parameters at baseline and after 6months of follow-up
- Secondary Outcome Measures
Name Time Method Reduction of liver volume and liver parameters (GOT/GPT) in patients with NAFLD/NASH by administration of antiplatelet therapy<br><br>Diagnosis and evaluation of course of liver volume and GOT/GPT are obtained by liver MRI and blood drawing at baseline and after 6months of follow-up